DHIAX
Price
$17.43
Change
+$0.18 (+1.04%)
Updated
Apr 23, 6:59 PM EST
VTISX
Price
$133.55
Change
+$1.28 (+0.97%)
Updated
Apr 23, 6:59 PM EST
Ad is loading...

DHIAX vs VTISX ᐉ Comparison: Which is Better to Invest?

Header iconDHIAX vs VTISX Comparison
Open Charts DHIAX vs VTISXBanner chart's image
Diamond Hill International I
Price$17.43
Change+$0.18 (+1.04%)
VolumeN/A
CapitalizationN/A
Vanguard Total Intl Stock Idx Instl Sel
Price$133.55
Change+$1.28 (+0.97%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
DHIAX vs VTISX Comparison Chart

Loading...

VS
DHIAX vs. VTISX commentary
Apr 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DHIAX is a Hold and VTISX is a Hold.

FUNDAMENTALS
Fundamentals
VTISX has more cash in the bank: 425B vs. DHIAX (132M). VTISX pays higher dividends than DHIAX: VTISX (3.32) vs DHIAX (0.87). DHIAX was incepted earlier than VTISX: DHIAX (5 years) vs VTISX (8 years). DHIAX is a more actively managed with annual turnover of: 21.00 vs. VTISX (4.00). DHIAX has a lower initial minimum investment than VTISX: DHIAX (2500) vs VTISX (3000000000). DHIAX annual gain was more profitable for investors over the last year : 9.07 vs. VTISX (6.12).
DHIAXVTISXDHIAX / VTISX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years8 years-
Gain YTD3.4171.973173%
Front LoadN/AN/A-
Min. Initial Investment250030000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets132M425B0%
Annual Yield % from dividends0.873.3226%
Returns for 1 year9.076.12148%
Returns for 3 years3.02-7.02-43%
Returns for 5 yearsN/A16.16-
Returns for 10 yearsN/AN/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VMI213.531.82
+0.86%
Valmont Industries
FAST67.510.06
+0.09%
Fastenal Company
VIA10.86N/A
N/A
Via Renewables
EPIX6.40N/A
N/A
ESSA Pharma
AUTL4.48-0.08
-1.75%
Autolus Therapeutics plc